MultiOmic Health, a leading AI-enabled drug discovery company, announces the identification of novel patient endotypes and the development of proprietary biomarkers for stratifying diabetic kidney disease (DKD) patients.
Nxera Pharma and Antiverse have today announced a multi-target partnership and licensing agreement to design antibodies for G-protein coupled receptors (GPCRs).
Attending the BIA’s TechBio UK conference this year offered an incredible opportunity to witness the ingenuity and innovation driving the future of life sciences.
The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.
Read the BIA's 2024 TechBio report to learn the current state of the sector and to read case studies from companies on the vanguard of innovation within the field.
The BIA’s policy and public affairs team attended the conferences of the three major UK parties this year. This is a key point in the political calendar and allows us to highlight the sector through fringe events, meet policymakers, and get a sense of the political environment.
The political party conference season is in full swing, and the BIA is out in force in Liverpool for the Labour Party conference this week. I'm heartened to see the focus in ministerial speeches and the fringe on topics close to our hearts. Read on for updates on the Lib Dem conference, West Streeting speech and Invest in Women Taskforce.
In this blog, Dr Emma Lawrence, Senior Policy and Public Affairs Manager, BIA, shares more about the launch of our new inaugural Data, AI and Genomics Advisory Committee, a key initiative to support the growing techbio community in the UK.
With a little over eight weeks to go to London Life Sciences Week (LLSW), we are launching a new website - lifesciencesweek.london - and lifting the lid on all that is happening to make the UK the place to be for life sciences this November. Continue reading for updates on NHS, £12 million Innovate UK funding, and more!
The studies presented this week at the Society of Neurointerventional Surgery (SNIS) underline the company’s rigorous evidence-based approach to developing and validating novel AI solutions that can help to optimize patient care across stroke networks.
The project will evaluate the real-world impact of Brainomix’s e-Lung imaging software to improve the identification and access to treatment for people with progressive pulmonary fibrosis in the US.
With the Prime Minister calling a snap election set for 4 July, the BIA’s attention has turned to preparing for the next government. Meanwhile, Parliament Day, our flagship day of parliamentary engagement, has been postponed to the autumn. Official engagements with civil servants have also been restricted in accordance with the pre-election period of sensitivity.
With a general election widely expected to be called later this year, the BIA’s long-established relationships with senior parliamentarians have been of particular importance this quarter. From launching the Labour Party’s Life Science Sector Strategy in Stevenage in January to hosting Science Minister Andrew Griffith MP at our Gala Dinner, we continue to represent the sector at the highest levels.
The BioIndustry Association (BIA) continued to represent the innovative life science and biotech sector to Ministers and senior policymakers between July and October 2023.
TechBio 2023: UK driving the AI revolution, a new report by the BioIndustry Association (BIA) highlights the UK TechBio sector as thriving, with a growing number of companies pioneering groundbreaking products and services, seamlessly integrating biotechnology and technology.
